In 2015 a new standard for stroke therapy was established based on five landmark clinical trials. These studies confirmed that blocked blood vessels in stroke patients could be opened by catheter guided stent retrievers and this innovative therapy led to remarkable improvement in clinical outcomes. The new stent retrievers were typically used in combination with tissue plasminogen activator (tPA). The comparison groups in these new studies typically received standard therapy with tPA alone, which has been the standard of care for stroke therapy for 20 years.
Among the new trials, the RAPID software was used to select patients for enrollment in the EXTEND-IA and SWIFT PRIME studies. These two studies achieved the best results ever obtained in an endovascular stroke study - 71% good outcome rate in EXTEND-IA and 60% in the SWIFT PRIME study.
Since 2015, there have been 9 randomized trials of endovascular therapy for treatment of acute stroke. Three of these trials used RAPID to select optimal patients for enrollment. The trials that used RAPID achieved substantially larger clinical benefits than the other trials. The absolute risk reductions shown here illustrate the difference in the favorable outcome rates in the endovascular arm vs. the medical control arm for each trial. The risk reductions of 31% and 36% achieved in EXTEND – IA and DAWN are the largest ever achieved in an acute stroke study.